Division of Translational Oncology

The Division of Translational Oncology was created to spearhead basic and translational research within the Department of Radiation Oncology.

The goals of the division are to accelerate discoveries in the lab pertaining to cancer genomics, radiogenomics, genomic instability, and mechanisms of cellular response to radiation and other cancer therapeutics.

Our investigators focus on translating key discoveries in the lab into innovative clinical trials using radiotherapy and combined-modality treatments.


Research projects

  • Defining the molecular determinants of immunotherapy efficacy. We are using genomic approaches to determine why patients are sensitive or resistant to immune checkpoint blockade.
  • Elucidating the drivers of metastasis
  • Characterizing the different roles of Rad51 mediators
  • Studying DNA replication and recombination, chromosome dynamics, and human genetics
  • Applying high-throughput sequencing technologies for cancer biomarker discovery and diagnostics
  • Studying the genomics of head and neck cancers and radiation response
  • Researching radiogenomics
  • Identifying how long noncoding RNAs control cellular behavior in response to stressors such as DNA damage and oncogene expression through the use of a combination of biochemistry, cellular biology, mouse genetics, and functional genomics
  • Studying mechanisms of radiation-induced damage and the clinical basis of radiation resistance


Timothy A. Chan
Director, Division of Translational Oncology

Zvi Fuks
Member, Memorial Sloan Kettering

Adriana Haimovitz-Friedman
Attending Radiation Biologist

Daniel Higginson
Assistant Attending

William Lee
Assistant Attending
Affiliate, Computational Biology

Simon Powell
Chair, Department of Radiation Oncology

Nadeem Riaz

Adam Schmitt
Assistant Attending


Timothy Chan
1275 York Ave – Box 22
New York, NY 10065